Clinical Research
Acute Myocardial Infarction
Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction

https://doi.org/10.1016/j.jacc.2007.02.040Get rights and content
Under an Elsevier user license
open archive

Objectives

This study investigated relationships between plasma myeloperoxidase (MPO), protein oxidation markers, and clinical outcome retrospectively in patients after acute myocardial infarction (MI).

Background

Reactive oxidants are implicated in cardiovascular disease, and elevated plasma MPO is reported to predict adverse outcome in acute coronary syndromes.

Methods

Detailed demographic information, radionuclide ventriculography, neurohormone measurements, and clinical history were obtained for 512 acute MI patients at hospital admission. Plasma levels of MPO and protein carbonyls were measured in patients and 156 heart-healthy control subjects. 3-Chlorotyrosine was measured in selected patients. Patient mortality was followed for 5 years.

Results

Plasma MPO and protein carbonyl concentrations were higher in MI patients 24 h to 96 h after admission than in control subjects (medians: MPO 55 ng/ml vs. 39 ng/ml, and protein carbonyls 48 pmol/mg vs. 17 pmol/mg protein, p < 0.001 for each). Both markers were significantly correlated with each other and with cardiovascular hormone levels. Chlorotyrosine was not elevated in patients with high MPO or carbonyl levels. Above-median levels of MPO but not protein carbonyls were independently predictive of mortality (odds ratio 1.8, 95% confidence interval 1.0 to 3.0, p = 0.034). Patients with above-median MPO levels in combination with above-median plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) or below-median left ventricular ejection fraction (LVEF) had significantly greater mortality compared with other patients.

Conclusions

Myeloperoxidase and protein carbonyl levels are elevated in plasma after acute MI, apparently via independent mechanisms. High MPO is a risk factor for long-term mortality and adds prognostic value to LVEF and plasma NT-proBNP measurements.

Abbreviations and Acronyms

ANP
atrial natriuretic peptide
BNP
brain natriuretic peptide
IQR
interquartile range
LVEDV
left ventricular end-diastolic volume
LVEF
left ventricular ejection fraction
LVESV
left ventricular end-systolic volume
MI
myocardial infarction
MPO
myeloperoxidase
NT-proANP
amino-terminal pro-atrial natriuretic peptide
NT-proBNP
amino-terminal pro-brain natriuretic peptide
PTCA
percutaneous transluminal coronary angioplasty

Cited by (0)

This research was supported by grants from the Health Research Council, the National Heart Foundation of New Zealand, and the National Research Centre for Growth and Development. Dr. Pilbrow was the recipient of a University of Otago Postgraduate Scholarship, Dunedin, New Zealand, and Professor Richards holds the National Heart Foundation Chair of Cardiovascular Studies. Dr. Winterbourn’s laboratory has a commercial interest in assay kits for protein carbonyls. Ms. Mocatta and Dr. Pilbrow contributed equally to the study.